The pelvis is often called the keystone of upright movement. It helps explain how human ancestors left life on all fours ...

Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine at the University of ...

Osteoblasts act in a group to make bone over the course of several months. However, how osteoblasts cooperate with each other in vivo is still unknown. Now, researchers at Osaka University established ...

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine at the University of ...

Osteoblasts derived from MSCs are cells required for bone formation. Oxidative phosphorylation produces a lot of ATP and other products including NAD+ and ROS. These factors play important roles in ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...